Role of prostacyclin in the treatment of primary pulmonary hypertension (Q40581698)

21 September 2017

1 reference

title

Role of prostacyclin in the treatment of primary pulmonary hypertension (English)

1 reference

21 September 2017

G Cremona

1

1 reference

PubMed ID

7840058

21 September 2017

T Higenbottam

series ordinal

2

1 reference

PubMed ID

7840058

21 September 2017

language of work or name

English

0 references

publication date

1 January 1995

1 reference

American Journal of Cardiology

21 September 2017

1 reference

21 September 2017

75

1 reference

21 September 2017

3

1 reference

21 September 2017

67A-71A

1 reference

Primary pulmonary hypertension. A national prospective study

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

Primary pulmonary hypertension: natural history and the importance of thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

Regression in thromboembolic type of primary pulmonary hypertension during 2 1/2 years of antithrombotic therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

Captopril as treatment for patients with pulmonary hypertension. Problem of variability in assessing chronic drug treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

The CREST syndrome--successful reduction of pulmonary hypertension by captopril

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

Calcium channel blockers in primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

Fatal Outcome following Nifedipine for Pulmonary Hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

Pulmonary hypertension and increased vasoreactivity caused by repeated indomethacin in sheep.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary artery hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

A comparison of the acute hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

Prostacyclin and acetylcholine as screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

Long-term clinical results after vasodilator evaluation in patients with primary (unexplained) and secondary precapillary pulmonary hypertension: acute hemodynamic comparisons and long-term survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

The place of prostacyclin in the clinical management of primary pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2899%2980386-5

10.1016/S0002-9149(99)80386-5

7 January 2021

Identifiers

DOI

1 reference

21 September 2017

1 reference

PubMed ID

7840058